In most cases, complete surgical resection followed by radiation therapy offers the best chance of long-term control. Incomplete resection of the primary tumor makes controlling the disease more difficult and increases the odds of recurrence. The decision whether complete or incomplete surgery should be performed primarily depends on the anatomical location of the tumor and its proximity to vital parts of the central nervous system.<unk> s are relatively radioresistant, requiring high doses of radiation to be controlled. The proximity of<unk> s to vital neurological structures such as the brain stem and nerves limits the dose of radiation that can safely be delivered. Therefore, highly focused radiation such as proton therapy and carbon ion therapy are more effective than conventional x-ray radiation. There are no drugs currently approved to treat<unk> , however a clinical trial conducted in Italy using the PDGFR inhibitor Imatinib demonstrated a modest response in some<unk>  patients. The same group in Italy found that the combination of imatinib and sirolimus caused a response in several patients whose tumors progressed on imatinib alone.Erlotinib like EGFR inhibitors have been also reported to be effective in<unk> . Though EGFR mutation is not present in<unk>  yet EGFR expression might predict response to erlotinib (as shown in report by Dr Sameer Rastogi). A report of response to olaparib has been published.
Chordoma
Neurothekeoma
Brown tumor
Neuroma
Ependymoma
Germinoma
Ameloblastoma
Medulloblastoma